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Abstract
Background: Rare diseases (RDs) are often neglected because they affect a small percentage of the population
(6–8 %), which makes research and development of new therapies challenging processes. Easy access to high-quality
samples and associated clinical data is therefore a key prerequisite for biomedical research. In this context, Genetic
Biobanks are critical to developing basic, translational and clinical research on RDs. The Telethon Network of Genetic
Biobanks (TNGB) is aware of the importance of biobanking as a service for patients and has started a dialogue
with RD-Patient Organisations via promotion of dedicated meetings and round-tables, as well as by including
their representatives on the TNGB Advisory Board. This has enabled the active involvement of POs in drafting
biobank policies and procedures, including those concerning ethical issues. Here, we report on our experience
with RD-Patient Organisations who have requested the services of existing biobanks belonging to TNGB and
describe how these relationships were established, formalised and maintained.
Results: The process of patient engagement has proven to be successful both for lay members, who increased
their understanding of the complex processes of biobanking, and for professionals, who gained awareness of
the needs and expectations of the people involved. This collaboration has resulted in a real interest on the part
of Patient Organisations in the biobanking service, which has led to 13 written agreements designed to formalise this
process. These agreements enabled the centralisation of rare genetic disease biospecimens and their related data,
thus making them available to the scientific community.
Conclusions: The TNGB experience has proven to be an example of good practice with regard to patient
engagement in biobanking and may serve as a model of collaboration between disease-oriented Biobanks
and Patient Organisations. Such collaboration serves to enhance awareness and trust and to encourage the
scientific community to address research on RDs.
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Background
The term rare diseases (RDs) refers to approximately
5000–8000 individual diseases that affect an estimated
350 to 400 million people worldwide. Because RDs affect
a limited number of individuals (6–8 % of the popula-
tion), they are often neglected. Therefore, research and
development of new therapies are challenging processes
that require considerable effort [1].
RDs have often a genetic origin and, although etio-
logically heterogeneous, they can share cellular and mo-
lecular pathways. Understanding their pathological and
developmental bases may therefore lead to a new med-
ical classification system and the development of shared
therapeutic targets.
Given the nature of RDs, easy access to high-quality
samples and associated clinical data is a key prerequisite
for biomedical research. In this context, Genetic
Biobanks (GBs), which are resources of samples and data
that are collected, stored, processed, and distributed in
an organised system, are critical to the progress of basic,
translational and clinical research on RDs [2]. Therefore,
close interaction between GBs and clinical/diagnostic
centres is essential to maintaining well characterised
samples linked to updated clinical data. Additionally, the
involvement of RD Patient Organisations (POs) is essen-
tial if a critical mass of samples is to be obtained, as POs
can serve as liaisons between GBs and physicians in
collecting both samples and clinical data for research. A
strong collaboration between GBs and POs is also
fundamental to achieving the integration of sample data
stored in biobanks and clinical data stored in registries
or clinical databases. In this respect, the European FP7
program, RD-Connect, was designed to build an
integrated platform that links registries to GBs and to
clinical data for research on rare diseases [1, 3].
Over the last few years, the degree of involvement of
POs in biobanking activities has increased greatly; POs
have evolved from mere participants to active collabora-
tors. This change is also due to the fact that patients,
unhappy with the speed of research into their respective
diseases, have started to look with interest at the oppor-
tunities provided by the biobanks. Individual patients
and POs’ representatives are now part of the decision-
making governance structure of national and inter-
national biobanks or biobank networks [4]. Here, they
can express their points of view and expectations of
research on their samples as well as participate in
drafting ethical guidelines and operational procedures
concerning sample use/transfer and data sharing. Within
the rare disease patients’ community, there are also ex-
amples of those who have invested their own resources
in the establishment of new own biobanks [4–6].
Here, we report on our experience with rare disease
patient organisations that have requested the services
(sample and data collection, preparation, storage and
distribution) of existing biobanks belonging to the
“Telethon Network of Genetic Biobanks” and describe
how these relationships have been established, forma-
lised and maintained.
Methods
Telethon Network of Genetic Biobanks
The Telethon Network of Genetic Biobanks (TNGB) [7],
currently composed of 11 Italian non-profit repositories,
was established in 2008 within the framework of a research
project financially supported by the Telethon Foundation.
Currently, TNGB stores more than 90,000 biological sam-
ples representing approximately 850 distinct rare genetic
diseases. Responsibilities for harmonisation and standard-
isation – with regard to the collection, preparation,
transport, storage, and distribution of samples – have been
shared by all partners and are stated in the Network
Charter.
One of the primary objectives of the project was to
interconnect already well-established Italian GBs, most
of which have been operating since the 1970s–1980s,
through a unique and centrally coordinated IT infra-
structure designed to (i) standardise and harmonise the
procedures; (ii) minimise biases that might arise from
heterogeneity in sample quality; (iii) develop a common
sample access policy based on predefined criteria. An-
other central aim was to promote GB services within
POs, with the goal of fostering their active participation
and sharing benefits with them in terms of research
findings [2]. To make this strategy practical, a represen-
tative of the RD Patient Organisation “UNIAMO FIMR”
(an Italian Federation of approximately 100 Associations
of patients with rare diseases) [8] was invited to join the
TNGB Advisory Board and to contribute to the develop-
ment of the TNGB. This arrangement has been in place
since the conception of the TNGB.
The TNGB is not only a national reality. In fact, the 11
TNGB partners are also members of the EuroBioBank
network, the first European network of GBs for rare dis-
eases [6]. Moreover, since 2012, TNGB has also been an
associated partner of the European RD-Connect project
[9], which aims to connect databases, registries, bio-
banks and clinical bioinformatics for rare disease re-
search [1, 3]. In addition, TNGB participates in the
Biobanking and Biomolecular Resources Research Infra-
structure [10].
Engagement of Patient Organisations
The TNGB has begun a dialogue with the public, including
patient organisations, by promoting several events (a total
of 34 events over 9 years). This activity, publicised by an
information leaflet, has helped to explain the purposes of
biobanks and how they operate, as well as to give patients
Baldo et al. Orphanet Journal of Rare Diseases  (2016) 11:142 Page 2 of 8
and families the opportunity to voice their perspectives,
needs and concerns.
Furthermore, as we mentioned in the previous section,
the participation of a PO representative on the TNGB
Advisory Board has been an effective way for patients to
be actively involved in drafting TNGB policies and in
sharing their perspectives on procedures concerning
ethical issues such as transparency, informed consent,
privacy, sample use and transfer, data sharing, commercial-
isation, return of results and incidental findings [11–13].
Several activities occurring within the framework of the
project “Determinazione rara”, financed by the Italian
Ministry of Labour and Welfare and UNIAMO FIMR
[14], have demonstrated additional examples of good
practice with regard to patients’ engagement in biobank-
ing. Through a series of organised roundtable sessions,
the lay members of patient organisations and the panel of
experts (biobankers, healthcare professionals, bioethicists,
jurists/lawyers) discussed ethical and legal concerns re-
lated to privacy and informed consent, sample ownership,
withdrawal of samples and consent, access to samples and
data, return of results and incidental findings. This ex-
tremely fruitful debate led to a draft of comprehensive in-
formed consent that became the official model adopted by
all the biobanks in the Network [15].
Agreements between TNGB and Patient Organisations
The interest of Patient Organisations in the biobank ser-
vice led to the formalisation of a working partnership via
a written agreement. An agreement template was drafted
(and approved by the TNGB Advisory Board) with the
aim of defining the terms and tasks of the parties viz.
the interested PO and one of the 11 Biobanks of the
Network. The selection of the Biobank is usually based
on some pre-defined criteria, including geographical
proximity to the PO’s head office and the affinity of the
disease to the pre-existing collections.
Briefly, the agreement template includes the purpose of
the agreement, a detailed description of roles and respon-
sibilities, a specification of the duration of the service and
a clause on termination, and the parties’ signatures. Con-
cerning the parties’ roles and responsibilities, the PO shall
undertake to (i) identify a representative who keeps associ-
ated families and referring clinicians informed of the Bio-
bank’s activities and policies; (ii) promote the recruitment
of patients and relatives; and (iii) organise shipment of
biospecimens to the assigned Biobank, which, in its role,
undertakes to (i) provide the service of biobanking accord-
ing to TNGB policies and SOPs; (ii) publish the sample
collection on the TNGB online catalogue; and (iii) keep
the PO’s representative informed of the sample workflow
and availability of potential findings resulting from the dis-
tribution service (Fig. 1). The agreement template is avail-
able as Additional file 1. The parties sign the agreement
for a period of one year, as a trial period. The trial serves
to adapt the several procedures and to share forms already
implemented by the Biobanks of the Network and, even-
tually, to decide whether the agreement should be
undertakes to
provide a biobanking service for the PO in 
accordance with the procedures defined in 
TNGB SOPs and Charter
appoint the most suitable GB among the 
Partners to host the PO collection
include new PO samples in the TNGB online 
catalogue
update the PO with data concerning requests 
and the distribution service as well as the 
justification of potential sample request 
rejections 
put researchers requesting clinical data in 
touch with the curator of  a registry or clinical 
database (if any) 
make sure that the PO is properly cited in the 
“Acknowledgments” section of potential 
publications resulting from PO samples  
inform the PO of any modifications to the 
TNGB forms, governance and policies
undertakes to
appoint a representative to liaise with the 
assigned GB
arrange  the biospecimen shipment to the GB
provide the referring clinicians with all details 
and forms concerning the sample shipment 
and biobanking 
inform the GB of the availability of a patients’ 
registry or a clinical database 
promote the TNGB and Telethon among its 
associated families and partners and support 
their initiatives 
Fig. 1 Tasks of the Parties
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renewed. In the event that the agreement is not renewed,
the PO shall decide whether they wish to withdraw sam-
ples and related consents or transfer the samples to an-
other Biobank. The agreement also includes, as annexes,
the following forms: (i) subject and data sheet, tailored to
clinical features of the disease to optimise data collection;
(ii) informed consent form for seeking the subject’s con-
sent to biobanking; (iii) material transfer agreement
(MTA) template, made available for the PO’s consultation.
Indeed, while the informed consent model was drafted
through an iterative process involving the patients (as de-
scribed above), the MTA template, as a legal instrument
that defines terms for the transfer of biological materials
between two Institutions [16], was drafted by the Telethon
Technology Transfer Office and subsequently discussed
during a meeting of the TNGB Advisory Board, which in-
cluded a representative of the RD Patient Organisation.
Once the agreement is signed, the Biobank staff work
in close collaboration with the PO’s representative and
the panel of referred clinicians to define the sample
type(s) to be collected and the operative procedures re-
lated to their sampling and shipment. Sample collections
from patients occur in various ways and are generally
organised to coincide with the PO’s biannual/annual
meetings (which update members on the latest research
and developments concerning their diseases) or during
open days, which include a systematic multidisciplinary
assessment of the patients. To support the PO, the dir-
ector of the involved GB always attends the meetings to
(i) provide further details concerning the terms of the
agreement; (ii) emphasise the importance of making
genuine and conscious choices before consenting to bio-
banking; (iii) address potential questions and concerns
during the process of seeking informed consent; (iv) give
further technical details about data sharing practices
through the use of the legal instrument (MTA); (v) em-
phasise that the potential benefits derived from the use
of the samples can impact not only the health of the in-
dividual but also the entire community in accordance
with the concept of the “common heritage” in relation
to the human genome, invoked by UNESCO and HUGO
[17–19]; (vi) update the PO about samples and data
workflow, possible research results and publications ob-
tained from the sample collection.
To increase the visibility of the samples collected under
the agreements and to spread knowledge of the sustained
engagement and involvement of patients in biobanks, a
web page has been created on the TNGB web site that is
entirely dedicated to activities with POs [20].
Results
Events and meetings have been very effective in main-
taining patients’ interactions with professionals and thus
increasing their literacy and empowerment. This two-
way information exchange has allowed the professionals,
on the one hand, to provide information that helps pa-
tients understand (i) the length of the diagnosis and re-
search processes, (ii) the measures for sharing data with
researchers requesting samples, (iii) the procedures for
the return of results, and (iv) the international and na-
tional recommendations and norms regulating biobank-
ing. The patients, on the other hand, have had the
opportunity to raise the awareness of the professionals
by (i) providing information on their values, priorities,
needs, perspectives and expectations concerning the bio-
bank services; and (ii) sharing their points of view on
ethical issues with regard to informed consent, data
sharing and return of findings. From the several debates
that occurred, it became clear that the concerns and res-
ervations – expressed by both patients and the public –
are not particularly related to privacy and data sharing
issues but rather to the fact that the use of their samples
is often limited to the research centres that collected the
samples. Another critical issue concerns the difficulty of
obtaining access to the results of research performed
using their samples and data. The issue of the mode of
returning results, including incidental ones, has indeed
generated a broad debate with the patients. Based on the
general ethical principle that patients have the right to
decide if they want to know or not know the results of
the research, the central question is who should commu-
nicate the results and which results should be returned,
as they can differ in validity, predictive power and clin-
ical significance [21]. Concerning this last point, we have
helped patients understand the objective difficulty of
communicating intermediate research results (that do
not have immediate applicability) and, in addition, dis-
closed that while the Biobank staff must do everything
within its power to ensure the return of research results,
they may not have the specific expertise required to
communicate such results. In this event, the Biobank
staff should be acting as a link between the researchers
and the people who are best suited to contact the pa-
tients, such as the referring clinician together with the
geneticist. This option has been introduced in the TNGB
form seeking patients’ consent, thus inviting patients to
indicate their preferred referral centre.
Agreements between Patient Organisations and the
Genetic Biobanks of the Network
The various events mentioned above have increased aware-
ness, trust and interest in the biobank service on the part of
Patient Organisations and, as of now, have led to 13 agree-
ments. The first was signed in December 2009 between the
Ring 14 Italian Association and the Galliera Genetic Bank,
based on the biobank staff ’s experience in the diagnosis of
chromosomal disorders [22]. Since then, another 12 POs
have expressed their interest in TNGB services and
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Table 1 Summary information concerning the agreements currently in place
Genetic Biobank Patient Organisation Disease Starting date Patient Registry/Clinical
database
No. of subjects
Cell line and DNA Biobank from patients
affected by genetic diseases
(TNGB Coordinator)
Associazione Italiana Sindrome di Poland Poland S. (ORPHA2911) Feb 2014 Clinical database 238
LND Famiglie Italiane Lesch-Nyhan disease (ORPHA510) Oct 2014 Italian Patient Registry
(in progress)
6
F.O.P. Italia Onlus Fibrodysplasia ossificans progressive (ORPHA337) Jan 2015 No 4
Galliera Genetic Bank (TNGB Partner 1) Ring 14 International Ring 14 S. and other chromosome 14 related
diseases (ORPHA1440)
Dec 2009 Clinical database 197
Associazione Nonsolo15 dup15q S. (ORPHA3306) Jul 2012 No 40
Associazione Mowat Wilson Mowat-Wilson S. (ORPHA2152) Jul 2012 No 27
Gruppo Famiglie Dravet Dravet S. (ORPHA33069) May 2013 Clinical database 56
ASSI Gulliver - Sindrome di Sotos Sotos S. (ORPHA821) Jul 2015 No 4
Cell lines and DNA Bank of Rett syndrome,
X-linked mental retardation and other
genetic diseases (TNGB Partner 3)
Associazione Sindrome di Alport Alport S. (ORPHA63) Oct 2013 Italian Patient Registry 247
Associazione Italiana Rett Rett S. (ORPHA778) Nov 2013 Italian and European
Patient Registry
95
ILA - Associazione italiana Angiodisplasie
ed Emangiomi Infantili
Vascular Malformations May 2014 No 24
Genomic and Genetic Disorders Biobank
(TNGB Partner 7)
Federazione Italiana Prader Willi Prader Willi S. (ORPHA739) Jul 2012 No 124
Cell line and DNA Bank of genetic
movement disorders and mitochondrial
diseases (TNGB Partner 9)
AISNAF - Associazione Italiana Sindromi
Neurodegenerative da Accumulo di Ferro
Neurodegeneration with brain iron accumulation
(ORPHA385)
May 2015 No 72














formalised agreements that involved five different TNGB
partners (Table 1). The 13 agreements have allowed TNGB
to centralise very rare samples in a unique catalogue: as of
now, TNGB has collected 2457 samples derived from 616
affected subjects and 518 relatives (Table 1). This result has
been achieved thanks, in part, to tailored procedures and
forms for collecting samples and associated data, developed
together with PO representatives and referring clinicians.
[23]. Concerning the outcomes derived from the online
visibility of these disease collections, 52 sample requests
from the international scientific community have been
processed, leading to the distribution of 791 biospecimens.
Figure 2 shows the workflow of samples in terms of
quantity and typology.
In line with the mission of the TNGB, the significant
increase in the variety of incoming and outgoing samples
reflects the Biobanks’ efforts to satisfy the current and
future demands of the researchers engaged in studies of
these rare diseases.
All samples and data collected under the agreements
were made available to the scientific community on the
basis of the access rules stated in the Network Charter
and shared with the PO’s representatives; this ensures
transparency and privacy protection throughout all
phases of the process. Three scientific papers (acknow-
ledging both the GB and the PO) resulting from the use
of the distribution service have been published [24–26].
The “Ring 14” collection is the best example of how this
model of cooperation has worked efficiently in terms of
both number of subjects recruited and their geographical
provenance. This result has been achieved thanks to the
recent creation of the second level association “Ring 14
International”, which has greatly facilitated the centralisa-
tion of samples and data of subjects with different
geographical origins (i.e., Italy, Europe, USA) into a single
biobank and a clinical database [27]. Indeed, the families,
being consciously involved in the collection process, have
felt themselves to be key players in fostering research on
their neglected disease. The availability of a centralised
collection of a critical mass of these extremely rare samples
has stimulated the researchers’ interest and prompted some
POs (i.e., Ring 14 International, Gruppo Famiglie Dravet,
AIRETT-Associazione Italiana Rett) to financially support
specific research projects selected through a peer-review
process. This involvement allows the POs to play an active
role in combating the disease from which they suffer [28].
Finally, the close ties between POs and GBs also facili-
tate the sharing of related clinical data and ongoing
work on integrating different RD resources in line with
the primary aim of RD-Connect.
Discussion
The process of public involvement in biobanks proved
to be successful for both the lay members and the pro-
fessionals involved. The public has been able to increase
their understanding of the complex processes of bio-
banking and has become more confident. At the same
time, professionals have gained knowledge of the needs
and expectations of the people involved and learnt to be
much more open to discussion concerning ethical issues.
The results of the first six years of activities within the
framework of these agreements have provided evidence
that POs’ collaboration is instrumental in centralising
both rare samples and associated data, as well as giving
visibility to these collections through the TNGB online
catalogue, which has captured the interest of inter-
national researchers studying neglected diseases. An-
other advantage of this approach is that POs have been
directly involved in research advancement by playing an
active role in the mechanisms of RD research and also
by contributing with seed grants to support research
projects focused on their diseases.
Another positive aspect of this collaboration can be
seen in the increased effort POs have put into sharing
their knowledge of biobanking with affiliated families
and with society as a whole to improve awareness of
patients’ rights and to address critical issues such as
privacy protection, use of samples and data, and return
of research findings to patients. This activity has enabled
POs to actively participate in drafting transparent regu-
lations and guidelines for sample management as well as
contribute to the alignment of some TNGB procedures
and forms with the needs of patients, such as the
renewed informed consent form, drafted within the
framework of the “Determinazione Rara” project, as well



















Fig. 2 Sample workflow per type in the framework of the
agreement Legend: Sample IN = incoming samples; Sample OUT =
outgoing samples; PBMCs = Peripheral blood mononuclear cells;
cell lines include fibroblasts, Epstein-Barr virus lymphoblasts, Induced
Pluripotent Stem Cells, amniocytes and trophoblast cells
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Finally, the TNGB-PO’s agreements demonstrate how
active collaboration between GBs and POs is critical to
rare disease biobanking.
Conclusions
To the best of our knowledge, this type of agreement is
unique at the national and international level. The set of
rules and tasks of the parties indeed ensures (i) quality
and proper use of the samples, (ii) individuals’ confidenti-
ality throughout the entire process and, more importantly,
(iii) visibility of and easy access to a specific sample collec-
tion for the interested biomedical community.
The TNGB experience may therefore serve as a
model of collaboration between disease-oriented
Biobanks and Patient Organisations, as it shows how
mutual respect and effective collaboration between
patients and the scientific community are essential to
the enhancement of awareness and trust, as well as to
the sharing of objectives and efforts to support
research on rare diseases.
Additional file
Additional file 1: Agreement template. (PDF 217 kb)
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